DexCom

263 articles with DexCom

• Exyte to build Dexcom's first manufacturing facility in Asia

  4/15/2021

  Exyte, world-renowned for the design and construction of high-tech facilities, has been awarded a fast-track project for Dexcom in Penang, Malaysia.

• Dexcom Schedules First Quarter 2021 Earnings Release and Conference Call for April 29, 2021 at 4:30 p.m. Eastern Time

  4/1/2021

  DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, April 29, 2021. Management will hold a conference call to review the company's first quarter 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day.

• Dexcom Promotes Jereme Sylvain to Chief Financial Officer

  3/23/2021

  DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the promotion of Jereme Sylvain to the role of Executive Vice President and Chief Financial Officer.

• Dexcom Announces Upcoming Virtual Conference Presentations - Feb 17, 2021

  2/17/2021

  DexCom, Inc. announced that management will present an update on the company at the following upcoming virtual investor conferences

• Dexcom Launches Inaugural Venture Capital Fund

  2/11/2021

  Dexcom Ventures to identify and invest in transformational technologies to advance long-term growth

• Dexcom Reports Fourth Quarter and Fiscal Year 2020 Financial Results

  2/11/2021

  DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2020.

• Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2020 and Provides Initial 2021 Outlook

  1/11/2021

  DexCom, Inc., the leader in continuous glucose monitoring, reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2020 to meet or exceed $567 million, an increase of 23% over the fourth quarter of 2019.

• Dexcom to Present at 39th Annual J.P. Morgan Healthcare Conference

  1/5/2021

  DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 39 th annual J.P. Morgan Healthcare Conference on January 11, 2021. The live presentation, which will occur virtually, is scheduled to begin at approximately 11:40 AM EST and will be concurrently webcast. The link to the webcast will be available on the Dexcom IR

• Dexcom to Host Investor Day on December 9, 2020

  11/3/2020

  DexCom, Inc. (NASDAQ:DXCM) announced today that it will host an Investor Day on December 9, from 8:30 AM until approximately 11:30 AM Pacific Standard Time (11:30 AM – 2:30 PM Eastern). The event, which will be held virtually, will include presentations from Dexcom management and industry leaders highlighting the company’s market opportunities, business strategy, innovation efforts and long-term financial outlook. Dexcom

• Dexcom Reports Third Quarter 2020 Financial Results

  10/27/2020

  DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2020. Third Quarter 2020 Financial Highlights: Revenue grew 26% versus the same quarter of the prior year to $500.9 million U.S. revenue growth of 29% and international revenue growth of 17% GAAP operating income of $94.1 million or 18.8% of revenue, an increase of 470 basis points comp

• Lilly and Dexcom team up on new program to help improve diabetes management

  10/7/2020

  Companies will partner to promote Lyumjev, Lilly's new rapid-acting insulin, with Dexcom G6 Continuous Glucose Monitoring, highlighting the benefits of using each

• Dexcom Schedules Third Quarter 2020 Earnings Release and Conference Call for October 27, 2020 at 4:30 p.m. Eastern Time.

  10/1/2020

  DexCom, Inc. announced that it plans to release its third quarter 2020 financial results after market close on Tuesday, October 27, 2020.

• Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic

  9/16/2020

  Data could support future efforts to make real-time CGM a standard tool for glycemic assessment in the hospital setting Real-world evidence will be gathered from healthcare providers and hospital institutions using real-time CGM with hospitalized patients SAN DIEGO--( BUSINESS WIRE )-- DexCom , Inc. ( NASDAQ:DXCM ), the leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today the first ever

• Dexcom Announces Upcoming Conference Presentation - Aug 10, 2020

  8/10/2020

  DexCom, Inc. announced that management will present an update on Dexcom

• Health Canada Authorizes Interim Use of Dexcom G6 CGM by Pregnant Women in Response to the COVID-19 Pandemic

  7/16/2020

  Last week, Health Canada temporarily authorized the adjunctive use of the Dexcom G6 Continuous Glucose Monitoring system by pregnant women with Type 1, Type 2, or gestational diabetes.

• Dexcom Schedules Second Quarter 2020 Earnings Release and Conference Call for July 28, 2020 at 4:30 p.m. Eastern Time

  6/30/2020

  DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2020 financial results after market close on Tuesday, July 28, 2020. Management will hold a conference call to review the company's second quarter 2020 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. investor rela

• KORE and Dexcom Partner to Bring Innovative Solution in Response to Global Pandemic

  6/16/2020

  KORE , the independent global IoT leader, today announced an ongoing partnership with Dexcom, Inc., the world leader in continuous glucose monitoring (CGM), to rapidly deliver an innovative remote patient monitoring solution to assist care providers during the COVID-19 global pandemic.

• Dexcom Announces Upcoming Conference Presentation on Tuesday, June 9, 2020

  6/4/2020

  DexCom, Inc. announced that management will present an update on Dexcom at the following upcoming investor conference

• DexCom Prices Offering of Upsized $1.05 Billion of 0.25% Convertible Senior Notes

  5/12/2020

  DexCom, Inc. announced the pricing of its offering of $1.05 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

• DexCom Announces Proposed Offering of $850.0 Million of Convertible Senior Notes

  5/11/2020

  DexCom, Inc. announced that it intends to offer, subject to market conditions and other factors, $850.0 million aggregate principal amount of Convertible Senior Notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.